JDRF, formerly known as the Juvenile Diabetes Research Foundation, has been a driving force in transforming how regulatory agencies evaluate and approve new diabetes technologies. Through strategic advocacy, patient-centered research funding, and direct collaboration with bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), JDRF has helped create regulatory pathways that are both rigorous and efficient. Their work has accelerated the arrival of life-changing devices—continuous glucose monitors (CGMs), insulin pumps, hybrid closed-loop systems, and the emerging artificial pancreas—to millions of people living with type 1 diabetes (T1D) around the world.

JDRF’s Mission and Historical Role in Diabetes Innovation

Founded in 1970 by parents of children with T1D, JDRF has grown into the largest global nonprofit funder of type 1 diabetes research. While its early focus was on finding a cure, the organization quickly recognized that better technologies could dramatically improve quality of life and reduce complications in the interim. By the 1990s, JDRF was investing heavily in the development of continuous glucose monitoring and insulin delivery systems, setting the stage for today’s integrated diabetes management ecosystem.

Critically, JDRF understood that even the most promising technologies would languish without clear, predictable regulatory pathways. In response, they launched the Artificial Pancreas Project in 2005, a landmark initiative that not only funded research but also built a regulatory framework from the ground up. This project forced FDA and other agencies to think about how to evaluate systems that combine a CGM, an insulin pump, and a control algorithm—a combination that didn’t neatly fit into existing medical device categories.

Today, JDRF continues to invest over $100 million annually in research, and a significant portion of that supports regulatory science and health policy. Their work ensures that innovative devices don’t just exist in labs—they reach the people who need them.

Advocacy and Policy: Shaping the Conversation at the FDA

JDRF’s advocacy efforts are not limited to writing letters or issuing statements. The organization has embedded regulatory expertise within its teams, allowing them to participate in FDA workshops, public meetings, and advisory committee discussions. One of their most significant achievements was the creation of the FDA’s Breakthrough Devices Program, which was inspired by earlier JDRF-led initiatives focused on the artificial pancreas.

JDRF successfully argued that T1D technologies, particularly those that automate insulin delivery, should be eligible for faster review without compromising safety. The program allows devices to receive priority review, interactive communication with FDA reviewers, and the possibility of deferring some premarket data collection in favor of post-market studies. As a result, devices like the Medtronic MiniMed 670G—the first hybrid closed-loop system—received FDA approval much more quickly than traditional timelines would have allowed.

Beyond the Breakthrough Devices Program, JDRF has also pushed for patient-focused drug development guidance, ensuring that the lived experience of people with T1D is considered during regulatory review. They have advocated for reduced clinical trial sizes where appropriate, using modern statistical methods and real-world evidence to supplement traditional trial data. This pragmatic approach has been adopted in several FDA guidance documents, including those for integrated CGM-pump systems.

Engagement with the European Medicines Agency

While much of JDRF’s regulatory work has focused on the FDA, they have also engaged the EMA to harmonize global approval processes. JDRF Europe has worked with national health technology assessment (HTA) bodies to ensure that devices approved by the EMA are quickly adopted in national health systems. This has been particularly important for the adoption of intermittently scanned CGMs (like the FreeStyle Libre) and full closed-loop systems in countries with single-payer healthcare.

Innovations in Diabetes Technologies Supported by JDRF

JDRF has supported a wide range of technologies, from discrete components to fully integrated systems. The table below summarizes key technologies and the role JDRF played in their development and regulatory approval.

  • Continuous Glucose Monitors (CGMs): JDRF funded pivotal trials for the Dexcom G4 Platinum, demonstrating that real-time CGM could reduce hypoglycemia and improve time-in-range. These data were instrumental in expanding Medicare coverage for CGMs. Later, JDRF-supported studies helped the Dexcom G6 and G7 achieve FDA clearance without fingerstick calibration.
  • Insulin Pumps: While insulin pumps predate JDRF’s major regulatory push, the Foundation funded interoperability standards that allowed pumps to communicate with CGMs and dosing algorithms. This led to the creation of the t:slim X2 pump with Control-IQ technology, which uses an algorithm developed at the University of Virginia with JDRF funding.
  • Closed-Loop Systems: JDRF’s most famous regulatory success is the hybrid closed-loop. They sponsored the first large-scale randomized controlled trials for the Medtronic 670G, the Omnipod 5, and the Tandem Control-IQ system. Each of these trials generated safety and efficacy data that directly shaped FDA labeling requirements.
  • Artificial Pancreas (Fully Automated): JDRF continues to fund research into fully automated, bihormonal systems that deliver both insulin and glucagon. The iLet bionic pancreas (Beta Bionics) is one example; JDRF helped design the clinical trial protocol and engaged the FDA on what endpoints would be acceptable for a device that makes all dosing decisions on behalf of the user.
  • Digital Health & Data Platforms: JDRF has supported the development of interoperable data platforms like Tidepool’s Loop, which allows patients to build their own closed-loop systems using FDA-cleared devices. Their advocacy helped Tidepool receive FDA clearance for the Loop app, the first of its kind.

Impact on Regulatory Pathways: A Detailed Look

Beyond individual devices, JDRF has changed how the FDA approaches entire categories of diabetes technology. Their contributions can be grouped into several key regulatory innovations.

The Breakthrough Devices Program (FDA)

JDRF was instrumental in the creation and refinement of this program. The program, codified in the 21st Century Cures Act, allows devices that provide more effective treatment or diagnosis of life-threatening conditions to be designated as breakthrough. JDRF’s early advocacy for the artificial pancreas demonstrated that an entire class of devices could be considered a breakthrough, not just individual products. As a result, nearly all automated insulin delivery systems have received breakthrough designation, speeding review times from an average of 18 months to under 9 months in some cases.

External link: FDA Breakthrough Devices Program

FDA Guidance Documents for Artificial Pancreas Systems

In 2012, JDRF and the FDA co-hosted a public workshop to discuss clinical trial design for the artificial pancreas. The output of that workshop directly informed the FDA’s 2016 guidance titled “Artificial Pancreas Device Systems – Regulatory Considerations.” This guidance established that safety endpoints could be assessed in supervised hotel studies before moving to outpatient environments, a revolutionary approach that reduced the cost and duration of trials.

JDRF also helped draft the primary endpoint for these studies: the percentage of time that blood glucose levels remain in the range of 70–180 mg/dL. This endpoint has become the gold standard for regulatory submissions and clinical research worldwide.

Real-World Evidence and Post-Market Studies

Recognizing that traditional premarket trials can never capture all real-world scenarios, JDRF has advocated for the use of real-world evidence (RWE) to support label expansions and post-market safety monitoring. For example, after the MiniMed 670G was approved, JDRF helped design the FUTURE study, which collected real-world data from thousands of users. Those data were used to support the approval of the 670G for children as young as 2 years old without requiring a new randomized controlled trial.

More recently, JDRF has worked with the FDA’s Center for Devices and Radiological Health (CDRH) to develop a framework for using data from patient-facing apps and cloud-based monitoring systems as evidence for approval. This paves the way for even more personalized diabetes care.

International Harmonization: A Global Impact

JDRF’s influence extends beyond the U.S. They have worked with the International Medical Device Regulators Forum (IMDRF) to align regulatory requirements for diabetes devices across countries. For instance, JDRF helped shape the IMDRF report on software as a medical device (SaMD), which clarified how algorithms that adjust insulin dosing should be regulated. This reduced duplication of clinical trials, allowing companies to submit the same data to multiple regulators.

External link: IMDRF SaMD Clinical Evaluation

Case Study: The Development of Closed-Loop Systems

The story of closed-loop systems epitomizes JDRF’s impact on regulatory pathways. When JDRF launched the Artificial Pancreas Project in 2005, no regulatory framework existed. The FDA treated any device that automatically adjusted insulin dosing as a new class of drug-device combination product, requiring extensive safety data and animal studies. JDRF responded by funding foundational research at the University of Virginia, the University of California Santa Barbara, and the Jaeb Center for Health Research.

In 2013, JDRF published a paper in Diabetes Care proposing a clinical trial roadmap that categorized studies into four phases: in silico (computer simulation), supervised inpatient, supervised outpatient (hotel or camp), and unsupervised outpatient. The FDA adopted this phased approach in its 2016 guidance.

The result was a series of successful approvals:

  • Medtronic MiniMed 670G (2016): The first hybrid closed-loop system, approved based on a 124-patient pivotal trial conducted at 10 U.S. centers with JDRF support. The approval came just 14 months after submission, compared to the typical 20-month timeline for a first-of-its-kind device.
  • Tandem Diabetes Care Control-IQ (2019): JDRF funded the DCLP3 study, a 168-patient randomized trial published in the New England Journal of Medicine. The data showed significant improvement in time-in-range (from 61% to 71%) with reduced hypoglycemia. The FDA approved Control-IQ in just 10 months.
  • Omnipod 5 (2022): The first tubeless hybrid closed-loop system, approved after a pivotal trial that included 125 adults and 112 children. JDRF researchers helped design the algorithm and provided regulatory guidance from the earliest stages.
  • iLet Bionic Pancreas (2023): JDRF supported the clinical development and FDA meeting process for this device, which requires no carb counting—a major milestone for user simplicity.

Each of these approvals set precedents for the next generation. JDRF continues to track real-world outcomes through its Registry platform, ensuring that any safety signals are rapidly communicated to regulators.

External link: JDRF Artificial Pancreas Research

Future Directions: Next-Generation Regulatory Pathways

JDRF is not resting on its successes. Several new regulatory frontiers are being actively shaped by the organization.

Digital Health and Algorithmic Regulation

As diabetes devices become increasingly software-defined, JDRF is working with the FDA’s Digital Health Center of Excellence to develop frameworks for the review of algorithm updates. Currently, any change to the insulin-dosing algorithm requires a new 510(k) submission, which can take months. JDRF is advocating for a total product life cycle (TPLC) approach, where companies can file a plan for iterative improvements and receive pre-approval for certain types of updates. This would allow algorithms to improve continuously, just like smartphone apps.

Patient-Reported Outcomes as Primary Endpoints

Traditional trials use time-in-range or HbA1c as primary endpoints. JDRF is funding research to validate patient-reported outcome (PRO) measures such as Hypoglycemia Fear, Diabetes Distress, and Sleep Quality. If the FDA accepts PROs as co-primary endpoints, it could open the door for devices that improve quality of life even if they don’t dramatically lower HbA1c. JDRF has already conducted a workshop with the FDA on this topic, and several device companies are incorporating PROs into their pivotal trials.

International Regulatory Convergence for Closed-Loop Systems

JDRF is part of a global coalition working with the International Council for Harmonisation (ICH) to create a common set of clinical trial requirements for diabetes devices. This would allow a single trial to support approvals in the U.S., Europe, Japan, and Australia, dramatically reducing costs and timelines. Early success is already visible; the iLet bionic pancreas was approved in the U.S. and the UK within weeks of each other, partly due to JDRF’s harmonization work.

Regulatory Pathways for Genomic and Cellular Therapies

While this article focuses on technologies, JDRF also continues to push for regulatory progress in disease-modifying therapies. They are working with the FDA’s Center for Biologics Evaluation and Research (CBER) on accelerated approval pathways for gene therapies that could protect or restore beta-cell function. JDRF’s regulatory experience from the artificial pancreas project is being directly applied to these nascent fields.

Conclusion

JDRF’s impact on the regulatory pathways for new diabetes technologies cannot be overstated. Through strategic advocacy, carefully designed clinical trials, and a deep understanding of both regulatory science and patient needs, the Foundation has fundamentally reshaped how innovations reach people with type 1 diabetes. The Breakthrough Devices Program, the artificial pancreas guidance, and the acceptance of real-world evidence all bear JDRF’s fingerprints.

As the organization turns its attention to digital health, international harmonization, and new endpoints, it is clear that JDRF will continue to be a critical bridge between ideas and cures—ensuring that every promising technology has a fair and efficient path to the people who need it most.

For more information on JDRF’s regulatory initiatives, visit JDRF Regulatory Policy.